Study of Metabolic Syndrome in Young Patients Who Are Acute Lymphoblastic Leukemia Survivors and Their Healthy Siblings

Study Overview
=================
Brief Summary
-----------------
RATIONALE: Gathering information about metabolic syndrome from young patients who have survived acute lymphoblastic leukemia (ALL) may help doctors learn more about the disease. PURPOSE: This phase I trial is studying the metabolic syndrome in young patients who have survived acute lymphoblastic leukemia and in healthy sibling volunteers.

Detailed Description
-----------------
OBJECTIVES: Determine the prevalence of the metabolic syndrome (MS) and its component traits (i.e., obesity, hypertension, dyslipidemia, and insulin resistance) in survivors of childhood acute lymphoblastic leukemia and in healthy sibling volunteers. Identify host- and treatment-related risk factors for MS. OUTLINE: This is a multicenter study. Patients' medical charts are reviewed and patients undergo anthropometric measuring (height and weight for BMI calculation and waist and hip circumferences) and blood pressure testing. Patients also complete questionnaires on their physical activity, diet, and family history over 30-45 minutes. Blood is collected to measure cytokines (e.g., adiponectin, leptin, interleukin-6, and C-reactive protein), fasting glucose, and fasting insulin. Healthy volunteers undergo anthropometric measuring and blood pressure testing (if they are seen in the clinic). They also complete a baseline medical history and questionnaires on their physical activity and diet.

Official Title
-----------------
Health Effects After Leukemia (HEAL) Research Study

Conditions
-----------------
Leukemia

Intervention / Treatment
-----------------
* Other: laboratory biomarker analysis
* Other: medical chart review
* Other: metabolic assessment
* Other: questionnaire administration
* Procedure: assessment of therapy complications


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: DISEASE CHARACTERISTICS: Meets one of the following eligibility criteria: Childhood acute lymphoblastic leukemia survivor Less than 22 years old at diagnosis Treated from 1990-2007 at one of the following locations: Fred Hutchinson Cancer Research Center and/or Children's Hospital and Regional Medical Center in Seattle, WA Vanderbilt Children's Hospital in Nashville, TN Meets 1 of the following treatment criteria: Completed conventional therapy ≥ 11 months ago and in first complete remission Received an allogeneic hematopoietic cell transplantation ≥ 11 months ago and in complete remission No evidence of recurrent disease Healthy volunteer Full sibling of enrolled cancer survivor Age 8-21 (if more than 1 eligible sibling, sibling of closest age is preferred) No history of cancer PATIENT CHARACTERISTICS: Able to speak, read, and write English PRIOR CONCURRENT THERAPY: See Disease Characteristics No active treatment for graft-vs-host disease Exclusion Criteria: Lack of ability to speak, read, and write English Active treatment for graft versus host disease

Ages Eligible for Study
-----------------
Minimum Age: 8 Years
Maximum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: laboratory biomarker analysis|nan|
|Other: medical chart review|nan|
|Other: metabolic assessment|nan|
|Other: questionnaire administration|will be obtained at a single clinic visit|
|Procedure: assessment of therapy complications|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of the metabolic syndrome (MS) and its component traits in these patients and in healthy volunteers |  | 2009-2011 | 
| Host- and treatment-related risk factors for MS |  | 2009-2011 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cancer survivor, healthy, no evidence of disease, long-term effects secondary to cancer therapy in children, childhood acute lymphoblastic leukemia in remission